Under the Medicare Drug Price Negotiation Program, the HHS secretary negotiates directly with manufacturers on the prices Medicare will pay for pharmaceuticals.

Senate Democrats and the Biden administration dropped plans to set drug price caps based on the amount paid in other high-income countries, during talks years ago to push through the law that empowered Medicare to negotiate down the cost of prescription medications.

The new guidance builds on previous years’ by increasing the focus on transparency and expanding, per statute, to include details about how Medicare Part B drugs and renegotiation processes will be incorporated into the program.

The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a new evaluation tool.

Bucks County has joined municipalities across the nation in suing major insulin manufacturers and drug price negotiating companies over an alleged “illegal

CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public comments due by June 26.

When Congress adopted the Inflation Reduction Act (IRA) in 2022, creating the Medicare Drug Price Negotiation Program (MDPNP), the bill did

Delaying Medicare’s ability to negotiate prices on small-molecule drugs until 13 years after FDA approval will decrease the amount of Medicare spending subject to price negotiation by billions of dollars annually.